15 December 2015Subscribe to our news feed

Testosterone Replacement Therapy and Mortality in Older Men

Testosterone Replacement Therapy and Mortality in Older Men

Testosterone Replacement Therapy and Mortality in Older Men.
Hackett GI. Drug Saf. 2015 Oct 19.

Despite a large prevalence of hypogonadism and increased testosterone prescribing over the past decade1-3, large studies report that only 10-12% of hypogonadal patients (comprising 40-45% of studied populations) are receiving treatment.4,5

One important reason for the under-treatment of men with testosterone deficiency is the widespread misperception about testosterone therapy on risk of cardiovascular disease. In this editorial we summarize a review paper published in the medical journal Drug Safety, which addresses the effects of testosterone therapy on cardiovascular risk factors, as well as mortality.6

KEY POINTS

  • There is a high level of evidence that hypogonadism is associated with increased all-cause mortality and reduced quality of life.
  • A large body of evidence shows that testosterone replacement therapy according to expert guidelines is safe and effective for men suffering from testosterone deficiency.
  • Emerging evidence shows that testosterone replacement therapy in hypogonadal men may reduce all-cause mortality.
  • Recent studies suggesting that testosterone replacement therapy may increase cardiovascular risk are severely flawed and do not exclude the possibility that the increased risk is related to hypogonadism and not the testosterone treatment.

What is known

Some well-established benefits of testosterone therapy in hypogonadal men are improvements in sexual function, mood, well-being, muscle mass and bone mineral density.7-9 Testosterone therapy improves body composition and metabolic profile, particularly in younger hypogonadal men and in those with metabolic disturbances.9

Despite concerns among clinicians and hypogonadal men, there is no evidence that testosterone therapy is associated with increased risk of prostate cancer10-12 or symptomatic benign prostatic hyperplasia.13 Currently, the main controversy surrounding testosterone therapy is its effect on heart disease.

What this review adds

The controversy about testosterone therapy and its putative negative impact on heart disease is based on a few fundamentally flawed studies.14-17 The review in the journal of Drug Safety points out their methodological problems and concludes that despite suggesting that testosterone therapy may increase cardiovascular risk, these studies do not exclude the possibility that the increased risk is related to hypogonadism and not the testosterone treatment.6 Along the same line, the European Medicines Agency (EMA) concluded that "there is no consistent evidence of increased cardiovascular risk with testosterone products".18 This was based on a European Union-wide review of testosterone medications, which did not find consistent evidence that testosterone therapy in men with hypogonadism increases the risk of heart problems.18

These conclusions are supported by a large body of research evidence from both epidemiological studies and clinical trials, accumulated over several decades. Multiple long-term studies show that hypogonadism is associated with increased cardiovascular and all-cause mortality.19-23 A recent study with a 14-year follow-up suggested a strong association between low baseline testosterone and incident myocardial infarction.24 One meta-analysis of community-based studies found that low testosterone levels at baseline are associated with a 35% and 25% increased risk of all-cause and cardiovascular mortality, respectively, 9 years later.25 The association between low testosterone levels and mortality risk persists even after strict adjustment for comorbidities.

A recent meta-analysis, performed on the largest number of studies collected so far, concludes that testosterone therapy is not related to any increase in cardiovascular risk, and that present data do not support a causal role between testosterone therapy and cardiovascular events.26 In accordance with another more recent meta-analysis9, in subjects with metabolic derangements a protective effect of testosterone therapy on cardiovascular risk is observed.26 This has also been demonstrated in several long-term registry studies lasting up to 8 years, where great improvements where seen in cardiovascular risk factors, including reductions in BMI, waist circumference, LDL (the “bad cholesterol”), triglycerides (blood fats), blood pressure, blood glucose, HbA1c (glycated hemoglobin, an important diabetes marker) and C-reactive protein (an inflammatory marker).27-33

If testosterone was truly bad for the heart – as the flawed studies suggested - one would expect that hypogonadal men with preexisting heart disease would be especially vulnerable to testosterone therapy. To the contrary, several studies show that testosterone therapy in men with chronic heart failure and angina is beneficial. In men with chronic stable angina pectoris, the ischemic threshold increased after 334 and 12 months35 of testosterone therapy. Notably, in the 12 month study, a marker of atherosclerosis (CIMT) tended to decrease in the testosterone group, and the protective effect of testosterone therapy on myocardial ischemia (lack of blood flow to the heart) was maintained throughout the 12 month treatment period without decrement.35 Interestingly, in men with chronic heart failure, testosterone therapy increased exercise capacity after 12 weeks36,37, predominantly through improvement in muscle performance.38

Ultimately, the goal with any medical treatment is to reduce mortality and increase longevity. As of this writing, two prospective studies have demonstrated reduced mortality in men treated with testosterone.20,39 In a study of 1031 men, testosterone treatment was initiated in 398 men (39%) during routine clinical care.20 After a follow-up of 20 months, mortality was 21% among untreated men versus 10% among testosterone treated men, with the greatest mortality reduction in younger men and those with type 2 diabetes.20 The second study of 587 men with type 2 diabetes had a follow-up of 5.8 years. 51 men were treated with testosterone for 2 years or more (mean testosterone therapy duration 3.5 years). Mortality rate was 20% in untreated hypogonadal diabetic men and 8.6 % in hypogonadal diabetic men who received testosterone therapy.39 Thus, both of these studies show that testosterone therapy reduces death by half and increases longevity in treated men.

In summary, the many beneficial effects of testosterone therapy can add up to a considerable benefit to men who suffer from testosterone deficiency. Testosterone therapy thus can be a valuable strategy to improve the metabolic profile, reduce body fat and increase muscle mass, which would ultimately reduce the risk of heart disease and increase longevity.

References

1. Baillargeon J, Urban RJ, Ottenbacher KJ, Pierson KS, Goodwin JS. Trends in androgen prescribing in the United States, 2001 to 2011. JAMA Intern Med. 2013 Aug 12;173:1465-6.
2. Gan EH, Pattman S, S HSP, Quinton R. A UK epidemic of testosterone prescribing, 2001-2010. Clin Endocrinol (Oxf). 2013 Oct;79:564-70.
3. Layton JB, Li D, Meier CR, Sharpless JL, Sturmer T, Jick SS, et al. Testosterone lab testing and initiation in the United Kingdom and the United States, 2000 to 2011. J Clin Endocrinol Metab. 2014 Mar;99:835-42.
4. Hall SA, Araujo AB, Esche GR, Williams RE, Clark RV, Travison TG, et al. Treatment of symptomatic androgen deficiency: results from the Boston Area Community Health Survey. Arch Intern Med. 2008 May 26;168:1070-6.
5. Mulligan T, Frick MF, Zuraw QC, Stemhagen A, McWhirter C. Prevalence of hypogonadism in males aged at least 45 years: the HIM study. Int J Clin Pract. 2006 Jul;60:762-9.
6. Hackett GI. Testosterone Replacement Therapy and Mortality in Older Men. Drug Saf. 2015 Oct 19.
7. Isidori AM, Giannetta E, Greco EA, Gianfrilli D, Bonifacio V, Isidori A, et al. Effects of testosterone on body composition, bone metabolism and serum lipid profile in middle-aged men: a meta-analysis. Clin Endocrinol (Oxf). 2005 Sep;63:280-93.
8. Saad F, Aversa A, Isidori AM, Zafalon L, Zitzmann M, Gooren L. Onset of effects of testosterone treatment and time span until maximum effects are achieved. Eur J Endocrinol. 2011 Nov;165:675-85.
9. Corona G, Giagulli VA, Maseroli E, Vignozzi L, Aversa A, Zitzmann M, et al. THERAPY OF ENDOCRINE DISEASE: Testosterone supplementation and body composition: results from a meta-analysis study. Eur J Endocrinol. 2015 Nov 4.
10. Khera M, Crawford D, Morales A, Salonia A, Morgentaler A. A new era of testosterone and prostate cancer: from physiology to clinical implications. Eur Urol. 2014 Jan;65:115-23.
11. Morgentaler A. Testosterone and prostate cancer: an historical perspective on a modern myth. Eur Urol. 2006 Nov;50:935-9.
12. Morgentaler A, Traish AM. Shifting the paradigm of testosterone and prostate cancer: the saturation model and the limits of androgen-dependent growth. Eur Urol. 2009 Feb;55:310-20.
13. Francomano D, Ilacqua A, Bruzziches R, Lenzi A, Aversa A. Effects of 5-year treatment with testosterone undecanoate on lower urinary tract symptoms in obese men with hypogonadism and metabolic syndrome. Urology. 2014 Jan;83:167-73.
14. Basaria S, Coviello AD, Travison TG, Storer TW, Farwell WR, Jette AM, et al. Adverse events associated with testosterone administration. N Engl J Med. 2010 Jul 8;363:109-22.
15. Xu L, Freeman G, Cowling BJ, Schooling CM. Testosterone therapy and cardiovascular events among men: a systematic review and meta-analysis of placebo-controlled randomized trials. BMC Med. 2013;11:108.
16. Vigen R, O'Donnell CI, Baron AE, Grunwald GK, Maddox TM, Bradley SM, et al. Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. JAMA. 2013 Nov 6;310:1829-36.
17. Finkle WD, Greenland S, Ridgeway GK, Adams JL, Frasco MA, Cook MB, et al. Increased risk of non-fatal myocardial infarction following testosterone therapy prescription in men. PLoS One. 2014;9:e85805.
18. European Medicines Agency. PRAC review does not confirm increase in heart problems with testosterone medicines - Committee recommends medicines can continue to be given for their authorised uses. Avaliable at: http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2014/10/WC500175207.pdf Accessed Dec 14, 2015. 2014.
19. Khaw KT, Dowsett M, Folkerd E, Bingham S, Wareham N, Luben R, et al. Endogenous testosterone and mortality due to all causes, cardiovascular disease, and cancer in men: European prospective investigation into cancer in Norfolk (EPIC-Norfolk) Prospective Population Study. Circulation. 2007 Dec 4;116:2694-701.
20. Shores MM, Smith NL, Forsberg CW, Anawalt BD, Matsumoto AM. Testosterone treatment and mortality in men with low testosterone levels. J Clin Endocrinol Metab. 2012 Jun;97:2050-8.
21. Tivesten A, Vandenput L, Labrie F, Karlsson MK, Ljunggren O, Mellstrom D, et al. Low serum testosterone and estradiol predict mortality in elderly men. J Clin Endocrinol Metab. 2009 Jul;94:2482-8.
22. Corona G, Monami M, Boddi V, Cameron-Smith M, Fisher AD, de Vita G, et al. Low testosterone is associated with an increased risk of MACE lethality in subjects with erectile dysfunction. J Sex Med. 2010 Apr;7:1557-64.
23. Vikan T, Schirmer H, Njolstad I, Svartberg J. Endogenous sex hormones and the prospective association with cardiovascular disease and mortality in men: the Tromso Study. Eur J Endocrinol. 2009 Sep;161:435-42.
24. Daka B, Langer RD, Larsson CA, Rosen T, Jansson PA, Rastam L, et al. Low concentrations of serum testosterone predict acute myocardial infarction in men with type 2 diabetes mellitus. BMC Endocr Disord. 2015;15:35.
25. Araujo AB, Dixon JM, Suarez EA, Murad MH, Guey LT, Wittert GA. Clinical review: Endogenous testosterone and mortality in men: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2011 Oct;96:3007-19.
26. Corona G, Maseroli E, Rastrelli G, Isidori AM, Sforza A, Mannucci E, et al. Cardiovascular risk associated with testosterone-boosting medications: a systematic review and meta-analysis. Expert Opin Drug Saf. 2014 Oct;13:1327-51.
27. Saad F, Yassin A, Doros G, Haider A. Effects of long-term treatment with testosterone on weight and waist size in 411 hypogonadal men with obesity Classes I-III: Observational data from two registry studies. Int J Obes (Lond). 2015;Jul 29 [Epub ahead of print].
28. Traish AM, Haider A, Doros G, Saad F. Long-term testosterone therapy in hypogonadal men ameliorates elements of the metabolic syndrome: an observational, long-term registry study. Int J Clin Pract. 2014 Mar;68:314-29.
29. Francomano D, Lenzi A, Aversa A. Effects of five-year treatment with testosterone undecanoate on metabolic and hormonal parameters in ageing men with metabolic syndrome. Int J Endocrinol. 2014;2014:527470.
30. Haider A, Saad F, Doros G, Gooren L. Hypogonadal obese men with and without diabetes mellitus type 2 lose weight and show improvement in cardiovascular risk factors when treated with testosterone: An observational study. Obes Res Clin Pract. 2014 Jul-Aug;8:e339-49.
31. Haider A, Yassin A, Doros G, Saad F. Effects of long-term testosterone therapy on patients with "diabesity": results of observational studies of pooled analyses in obese hypogonadal men with type 2 diabetes. Int J Endocrinol. 2014;2014:683515.
32. Saad F, Haider A, Doros G, Traish A. Long-term treatment of hypogonadal men with testosterone produces substantial and sustained weight loss. Obesity (Silver Spring). 2013 Oct;21:1975-81.
33. Yassin A, Doros G. Testosterone therapy in hypogonadal men results in sustained and clinically meaningful weight loss. Clin Obes. 2013 Jun;3:73-83.
34. English KM, Steeds RP, Jones TH, Diver MJ, Channer KS. Low-dose transdermal testosterone therapy improves angina threshold in men with chronic stable angina: A randomized, double-blind, placebo-controlled study. Circulation. 2000 Oct 17;102:1906-11.
35. Mathur A, Malkin C, Saeed B, Muthusamy R, Jones TH, Channer K. Long-term benefits of testosterone replacement therapy on angina threshold and atheroma in men. Eur J Endocrinol. 2009 Sep;161:443-9.
36. Pugh PJ, Jones RD, West JN, Jones TH, Channer KS. Testosterone treatment for men with chronic heart failure. Heart. 2004 Apr;90:446-7.
37. Malkin CJ, Pugh PJ, West JN, van Beek EJ, Jones TH, Channer KS. Testosterone therapy in men with moderate severity heart failure: a double-blind randomized placebo controlled trial. Eur Heart J. 2006 Jan;27:57-64.
38. Caminiti G, Volterrani M, Iellamo F, Marazzi G, Massaro R, Miceli M, et al. Effect of long-acting testosterone treatment on functional exercise capacity, skeletal muscle performance, insulin resistance, and baroreflex sensitivity in elderly patients with chronic heart failure a double-blind, placebo-controlled, randomized study. J Am Coll Cardiol. 2009 Sep 1;54:919-27.
39. Muraleedharan V, Marsh H, Kapoor D, Channer KS, Jones TH. Testosterone deficiency is associated with increased risk of mortality and testosterone replacement improves survival in men with type 2 diabetes. Eur J Endocrinol. 2013 Dec;169:725-33.
Last updated: 2017
G.GM.MH.04.2015.0334